Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Growth Inhibition of Human Lung Carcinoma Cells by ${\beta}>-lapachone$ through Induction of Apoptosis

Tabebuia avellanedae에서 유래된 ${\beta}>-lapachone$의 인체폐암세포 apoptosis 유발에 관한 연구

  • Choi, Byung-Tae (Department of Anatomy, Dong-Eui University College of Oriental Medicine) ;
  • Lee, Yong-Tae (Department of Physiology, Dong-Eui University College of Oriental Medicine and Biomedical Research Center of Oriental Medicine) ;
  • Choi, Yung-Hyun (Department of Biochemistry and Department of Biomaterial Control, Dong-Eui University College of Oriental Medicine)
  • 최병태 (동의대학교 한의과대학 해부학교실) ;
  • 이용태 (동의대학교 한의과대학 생리학교실 및 한방바이오연구센터) ;
  • 최영현 (동의대학교 한의과대학 생화학교실 및 대학원 바이오물질제어학과)
  • Published : 2005.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

The DNA topoismerase I inhibitor ${\beta}-lapachone$, the product of a lapacho tree (Tabebuia avellanedae) from South America, activates a novel apoptotic response in a number of cell lines. In the present report, we investigated the effects of ${\beta}-lapachone$ on the growth of human lung in human non-small-cell-lung-cancer A549 cells. Upon treatment with ${\beta}-lapachone$, a concentration-dependent inhibition of cell viability and cell proliferation was observed as measured by hemocytometer counts and MTT assay. The ${\beta}-lapachone-treated$ cells developed many of the hallmark features of apoptosis, including membrane shrinking, condensation of chromatin and DNA fragmentation. These apoptotic effects of ${\beta}-lapachone$ in A549 cells were associated with a marked induction of pro-apoptotic Bax expression, however the levels of anti-apoptotic Bcl-2 expression were decreased in a dose-dependent manner. Accordingly, elevated amount of cyclin-dependent kinase inhibitor p21 expression accompanied by up-regulation of tumor suppressor p53 was observed. By RT-PCR analyses, decrease in gene expression level of telomerase reverse transcriptase and telomeric repeat binding factor were also observed. Thus, these findings suggest that ${\beta}-lapachone$ may be a potential anti-cancer therapeutics for the control of human lung cancer cell model.

Keywords

References

  1. Evans, V.G. Multiple pathways to apoptosis. Cell Biol. Int. 17, 461-476, 1993.
  2. Shi, L., Nishioka, W.K,, Th'ng, J., Bradbury, E.M., Litchfield, D.W., Greenberg, A.H., Premature p34cdc2 activation required for apoptosis. Science 263, 1143-1145, 1994.
  3. Chiarugi, V., Magnelli, L., Turchetti, A., Cinelli, M., Cavari, S., Ruggiero, M., Cell survival and death programmes. Pharmacol. Res. 29, 101-110, 1994.
  4. Nagata, S. Apoptosis by death factor. Cell 88, 355-365, 1997.
  5. Lenaz, G., Bovina, e., Formiggini, G., Castelli, G.P. Mitochondria, oxidative stress, and antioxidant defences. Acta. Biochim. Pol. 46, 1-21, 1999.
  6. Antonsson, B., Martinou, J.C. The Bcl-Z protein family. Exp. Cell Res. 256, 50-57, 2000.
  7. Martin, S.J., Finucane, D.M., Amarante-Mendes, G.P., O'Brien, G.A, Green, D.R. Phosphatidylserine extemalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J. Biol. Chem. 271, 28753-28756, 1996.
  8. Steinhusen, D., Badock, V., Bauer, A, Behrens, J., Wittman -Liebold, B., Dorken, B., Bommert, K Apoptosis-induced cleavage of 13-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J. Biol. Chem. 275, 16345-16353, 2000.
  9. Schaffner-Sabba, K, Schmidt-Ruppin, K.H., Wehrli, W., Schuerch, A.R, Wasley, J.W. $\beta$-lapachone: synthesis of derivatives and activities in tumor models. J. Med. Chem. 27, 990-994, 1984.
  10. Li, C.J., Averboukh, L., Pardee, A.B. $\beta$-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem. 268, 22463-22468, 1993.
  11. Pardee, A.B., Li, Y.Z., Li, C.J. Cancer therapy with 13 -lapachone. Curro Cancer Drug Targets 2, 227-242, 2002.
  12. Lopes, J.N., Cruz, F.S., Docampo, R, Vasconcellos, M.E., Sampaio, M.C., Pinto, A.V., Gilbert, B. In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. Ann. Trop. Med. Parasitol. 72, 523-531, 1978.
  13. Goijman, S.G., Stoppani, AO. Effects of 13-lapachone, a peroxide-generating quinone, on macromolecule synthesisand degradation in Trypanosoma cruzi. Arch. Biochem. Biophys. 240, 273-280, 1985.
  14. Boothman, D.A, Schlegel, R, Pardee, A.B. Anticarcinogenic potential of DNA-repair modulators. Mutat. Res. 202, 393-411, 1988.
  15. Guiraud, P., Steiman, R, Campos-Takaki, G.M., SeigleMurandi, F., Simeon de Buochberg, M., Comparison of antibacterial and antifungal activities of lapachol and 13 -lapachone. Planta Med. 60, 373-374, 1994.
  16. Li, C.J., Wang, C, Pardee, A. B. Induction of apoptosis by $\beta$-lapachone in human prostate cancer cells. Cancer Res. 55, 3712-3715, 1995.
  17. Docampo, R, Cruz, F.S., Boveris, A, Muniz, RP., Esquivel, D.M. $\beta$-lapachone enhancement of lipid peroxidation and superoxide anion and hydrogen peroxide formation by sarcoma 180 ascites tumor cells. Biochem. Pharmacol, 28, 723-728, 1979.
  18. Shiah, S.G. Chuang, S.E., Chau, Y.P., Shen, S.C, Kuo, M.L. Activation of c-jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor 13 -lapachone-induced apoptosis through an oxidation-dependent pathway. Cancer Res. 59, 391-398, 1999.
  19. Planchon, S.M., Pink, J.J., Tagliarino, c. Bommann, W.G., Varnes, M.E., Boothman, D.A. 13-lapachone-induced apoptosis in human prostate cancer cells: involvement of NQ01/xip3. Exp. Cell Res. 267, 95-106, 2001.
  20. Planchon, M., Wuerzberger, S., Frydman, B., Witiak, D.T., Hutson, P., Church, D.R, Wilding, G., Boothman, D.A. $\beta$ -lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 55, 3706-3711, 1995.
  21. Don, M.J., Chang, Y.H., Chen, KK, Ho, L.K, Chau, YP. Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the $\beta$-lapachone-induced apoptosis of human prostate cancer cells. Mol. Pharmacol. 59, 784-794, 2001.
  22. Choi, Y.H., Kang, H.S., Yoo, M.A. Suppression of human prostate cancer cell growth by $\beta$-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1). J. Biochem. Mol. Biol. 36, 223-229, 2003.
  23. Weller, M., Winter, S., Schmidt, C, Esser, P., Fontana, A, Dichgans, J., Groscurth, P. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and $\beta$-lapachone. Int. J. Cancer 73, 707-714, 1997.
  24. Lai, C.C., Liu, T.J., Ho, L.K., Don, M.J., Chau, Y.P. $\beta$ -lapachone induced cell death in human hepatoma (HepA2) cells. Histol. Histopathol. 13, 89-97, 1998.
  25. Planchon, S.M., Wuerzberger-Davis, S.M., Pink, J.J., Robertson, K.A. Bornmann, W.G., Boothman, D.A Bcl-2 protects against $\beta$-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells. Oncol. Rep. 6, 485-492, 1999.
  26. Gupta, D., Podar, K., Tai, Y.T., Lin, B., Hideshima, T., Akiyama, M, LeBlanc, R, Catley, L., Mitsiades, N., Mitsiadcs, C., Chauhan, D., Munshi, N.C. and Anderson, K.C., $\beta$-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp. Hematol. 30, 711-720, 2002.
  27. Huang, L., Pardee, A.B. $\beta$-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells. Mol. Med. 5, 711-720, 1999.
  28. Choi, B. T., Cheong, J., Choi, Y.H. $\beta$-lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells. Anticancer Drugs 14, 845-850, 2003.
  29. Wuerzberger, S.M., Pink, J.J ., Planchon, S.M., Byers, K.L., Bornmann, W.G., Boothman, D.A. Induction of apoptosis in MCF-7:WS8 breast cancer cells by 13-lapachone. Cancer Res. 58, 1876-1885, 1998.
  30. Pink, J,J., Wuerzberger-Davis, S., Tagliarino, C, Planchon, S.M, Yang, X., Froelich, C.J., Boothman, D.A. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during $\beta$-lapachone-mediated apoptosis. Exp. Cell Res. 255, 144-155, 2000.
  31. Tagliarino, C. Pink, J.J., Dubyak, G.R, Nieminen, A.L., Boothman, D.A Calcium is a key signaling molecule in $\beta$ -lapachone-rnediated cell death. J. BioI. Chem. 276, 19150-19159, 2001.
  32. Arends, M.J., Morris, RG., Wylli, AH. Apoptosis. The role of the endonuclease. Am. J.Pathol. 136, 593-608, 1990.
  33. Cohen, J.J., Duke, R.C., Fadok, V.A., Sellins, K.S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10, 267-93, 1992.
  34. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849, 1993.
  35. Rosse, T., Olivier, R, Monney, L., Rager, M., Conus,S., Fellay, I., Jansen, B., Borner, C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391, 496-499, 1998.
  36. Miyashita, T., Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299, 1995.
  37. Harper, J.W., Adami, G.R, Wei, N., Keyomarsi, K., Elledge, S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75, 805-816, 1993.
  38. El-Deiry, W.S., Tokino, T., Velculesco, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, E.W., Kinzler, K.W., Vogelstain, B. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825, 1993.
  39. Hueber, A., Esser, P., Heimann, K., Kociok, N., Winter, S., Weller, M. The topoisomerase I inhibitors, camptothecin and $\beta$-lapachone, induce apoptosis of human retinal pigment epithelial cells. Exp. Eye Res. 67, 525-530, 1998.
  40. Kyo, S., Inoue, M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: How can we apply them for cancer therapy. Oncogene 21, 688-697, 2002.
  41. Poole, J.C, Andrews, L.G., Tollefsbol, T.O., Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269, 1-12, 2001.
  42. Cerni, C. Telomeres, telomerase, and myc. An update. Mutat. Res. 462, 31-47, 2000.
  43. Narayan, S., Jaiswal, A.S., Multani, A.S., Pathak, S. DNA damage-induced cell cycle checkpoints involve both p53-dependent and -independent pathways: role of telomere repeat binding factor 2. Br. J. Cancer 85, 898-901, 2001.
  44. Vaziri, H., West, M.D., Allsopp, R.C., Davison, T.S., Wu, Y.S., Arrowsmith, C.H., Poirier, G.G., Benchimol, S. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 16, 6018-6033, 1997.